Avillion announces positive results in MANDALA and DENALI Phase III trials of AstraZeneca's PT027, a fixed-dose combination of albuterol and budesonide, demonstrating significant benefits for asthma p
Go back to Avillion announces positive results in MANDALA and DENALI Phase III trials of AstraZeneca's PT027, a fixed-dose combination of albuterol and budesonide, demonstrating significant benefits for asthma p| REPROS THERAPEUTICS (NASDAQ: RPRX) | Delayed: 28.17 +0.19 (0.68%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $27.98 | 52 Week High | $3.48 | |||
| Open | $28.06 | 52 Week Low | $0.80 | |||
| Day High | $28.21 | P/E | N/A | |||
| Day Low | $27.65 | EPS | $-1.54 | |||
| Volume | 1,721,215 | |||||
